Document is current
Any future updates will be listed below
-
Authors
Liebschutz, Jane M. http://orcid.org/0000-0003-3492-1521
Subramaniam, Geetha A.
Stone, Rebecca
Appleton, Noa
Gelberg, Lillian
Lovejoy, Travis I.
Bunting, Amanda M.
Cleland, Charles M.
Lasser, Karen E.
Beers, Donna
Abrams, Catherine
McCormack, Jennifer
Potter, Gail E.
Case, Ashley
Revoredo, Leslie
Jelstrom, Eve M.
Kline, Margaret M.
Wu, Li-Tzy
McNeely, Jennifer
-
Clinical Trials BETA
Clinical trials referenced in this document:
nct04218201 at ClinicalTrials.govDocuments that mention this clinical trial
Subthreshold opioid use disorder prevention (STOP) trial: a cluster randomized clinical trial: study design and methods
https://doi.org/10.1186/s13722-023-00424-8
-
Funding
Funding for this research was provided by:
National Institute on Drug Abuse (UG1DA013035, UG1DA049436, UG1DA015815, UG1DA040317, UG1DA049435)
Agency for Healthcare Research and Quality (HS026120)
- License Information
-
More Information
Article History
Received: 13 April 2023
Accepted: 30 October 2023
First Online: 18 November 2023
Declarations
:
: The study was approved by the Biomedical Research Alliance of New York (BRANY). Each site’s own institutional review board ceded to the single IRB.
: All authors have reviewed the manuscript and have given consent for publication. The NIDA Clinical Trials Network publication committee has approved the manuscript.
: “This manuscript reflects the views of the authors and may not reflect the opinions, views, and official policy or position of the U.S. Department of Health and Human Services or any of its affiliated institutions or agencies.” Dr. Subramaniam was substantially involved in this project, consistent with her role as Scientific Officer. She has no conflicts to report. Dr. Jane Liebschutz is a consultant for Biomotivate, Inc.
